{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"70.0","value":"77.5"},{"groupId":"OG001","spread":"41.9","value":"86.3"},{"groupId":"OG002","spread":"46.3","value":"49.4"},{"comment":"Standard deviation was reported only when the number of participants analyzed were \\>= 3.","groupId":"OG003","spread":"NA","value":"443"},{"groupId":"OG004","spread":"107","value":"290"},{"groupId":"OG005","spread":"260","value":"435"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"4"},{"groupId":"OG005","value":"12"}],"units":"Participants"}],"description":"The Cmax is the maximum observed plasma concentration of Moxetumomab Pasudotox.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received IV 5 mcg/kg moxetumomab pasudotox on Days 1, 3, and 5 of every 28-day cycle and continued until complete response (CR), progressive disease (PD), initiation of alternative anticancer therapy, unacceptable toxicity, development of neutralizing antibodies, or another reason to discontinue therapy.","id":"OG000","title":"5 mcg/kg"},{"description":"Participants received IV 10 mcg/kg moxetumomab pasudotox on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until CR, PD, initiation of alternative anticancer therapy, unacceptable toxicity, development of neutralizing antibodies, or another reason to discontinue therapy.","id":"OG001","title":"10 mcg/kg"},{"description":"Participants received IV 20 mcg/kg moxetumomab pasudotox on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until CR, PD, initiation of alternative anticancer therapy, unacceptable toxicity, development of neutralizing antibodies, or another reason to discontinue therapy.","id":"OG002","title":"20 mcg/kg"},{"description":"Participants received IV 30 mcg/kg moxetumomab pasudotox on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until CR, PD, initiation of alternative anticancer therapy, unacceptable toxicity, development of neutralizing antibodies, or another reason to discontinue therapy.","id":"OG003","title":"30 mcg/kg"},{"description":"Participants received IV 40 mcg/kg moxetumomab pasudotox on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until CR, PD, initiation of alternative anticancer therapy, unacceptable toxicity, development of neutralizing antibodies, or another reason to discontinue therapy.","id":"OG004","title":"40 mcg/kg"},{"description":"Participants received IV 50 mcg/kg moxetumomab pasudotox on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until CR, PD, initiation of alternative anticancer therapy, unacceptable toxicity, development of neutralizing antibodies, or another reason to discontinue therapy.","id":"OG005","title":"50 mcg/kg"}],"paramType":"MEAN","populationDescription":"The PK Population consisted of all participants who received any amount of moxetumomab pasudotox and had a sufficient number of serum concentration measurements for computing PK parameters. The \"Overall Number of Participants Analyzed\" denotes the number of participants evaluated for this outcome measure.","reportingStatus":"POSTED","timeFrame":"Cycle 1 Day 1: pre-infusion; at 15 min during the infusion; at the end of infusion (approximately 5-7 minutes before the end of infusion); and at 1, 1.5, 2, 4, 8, and 12 h post infusion","title":"Maximum Observed Serum Concentration (Cmax) for Moxetumomab Pasudotox for Cycle 1 on Day 1","type":"PRIMARY","unitOfMeasure":"nanogram per milliliter (ng/mL)"}